Vertex announces u.s. fda approval for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 6 through 11 with certain mutations

Boston--(business wire)--vertex today announced the u.s. fda has approved trikafta for certain children with cystic fibrosis ages 6-11 years old.
VRTX Ratings Summary
VRTX Quant Ranking